I agree that this site is using cookies. You can find further informations here.
X
Shimazaki, Chihiro
209  results:
Search for persons X
?
1

The lymphocyte/monocyte ratio predicts the efficacy of isat..:

Shimazu, Yutaka ; Kanda, Junya ; Onda, Yoshiyuki...
Cancer Immunology, Immunotherapy.  73 (2024)  7 - p. , 2024
Link: https://doi.org/10.1007/..
 
?
2

Efficacy of elotuzumab for multiple myeloma deteriorates af..:

Nakamura, Naokazu ; Arima, Nobuyoshi ; Takakuwa, Teruhito...
Annals of Hematology.  , 2024
Link: https://doi.org/10.1007/..
 
?
3

Real-world data on induction therapy in patients with trans..:

Shimura, Yuji ; Shibayama, Hirohiko ; Nakaya, Aya...
International Journal of Hematology.  118 (2023)  5 - p. 609-617 , 2023
Link: https://doi.org/10.1007/..
 
?
4

Daratumumab plus bortezomib, cyclophosphamide, and dexameth..:

Suzuki, Kenshi ; Wechalekar, Ashutosh D. ; Kim, Kihyun...
Annals of Hematology.  102 (2023)  4 - p. 863-876 , 2023
Link: https://doi.org/10.1007/..
 
?
5

Impact of cytogenetic abnormalities in symptomatic multiple..:

Nakaya, Aya ; Shibayama, Hirohiko ; Uoshima, Nobuhiko...
Leukemia Research Reports.  20 (2023)  - p. 100395 , 2023
Link: https://doi.org/10.1016/..
 
?
6

The serum level of plasmin‐alpha2 plasmin inhibitor complex..:

Shimazaki, Chihiro ; Matsui‐Maegawa, Saori ; Kimoto‐Matsumura, Yayoi...
British Journal of Haematology.  202 (2023)  6 - p. 1209-1212 , 2023
Link: https://doi.org/10.1111/..
 
?
7

A retrospective analysis of clinical features and treatment..:

Fuchida, Shin-ichi ; Ogura, Mizuki ; Ishida, Tadao...
International Journal of Hematology.  , 2023
Link: https://doi.org/10.1007/..
 
?
8

Efficacy of elotuzumab for multiple myeloma in reference to..:

Shimazu, Yutaka ; Kanda, Junya ; Kosugi, Satoru...
Scientific Reports.  13 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
9

Anti‐CD38 antibody isatuximab monotherapy for Japanese indi..:

Sunami, Kazutaka ; Fuchida, Shin‐ichi ; Suzuki, Kenshi...
Hematological Oncology.  41 (2022)  3 - p. 442-452 , 2022
Link: https://doi.org/10.1002/..
 
?
10

Clinical impacts of frailty, poor performance status, and a..:

Kawaji-Kanayama, Yuka ; Muramatsu, Ayako ; Sasaki, Nana...
International Journal of Hematology.  115 (2022)  3 - p. 350-362 , 2022
Link: https://doi.org/10.1007/..
 
?
11

18F‐fluorodeoxyglucose‐positron emission tomography/compute..:

Imashuku, Shinsaku ; Tsunemine, Hiroko ; Shimazaki, Chihiro
eJHaem.  3 (2022)  3 - p. 1042-1043 , 2022
Link: https://doi.org/10.1002/..
 
?
12

Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-D..:

Sunami, Kazutaka ; Ikeda, Takashi ; Huang, Shang-Yi...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  8 - p. e751-e761 , 2022
Link: https://doi.org/10.1016/..
 
?
13

Real-world effectiveness and safety analysis of carfilzomib..:

Onda, Yoshiyuki ; Kanda, Junya ; Kaneko, Hitomi...
Therapeutic Advances in Hematology.  13 (2022)  - p. 204062072211045 , 2022
Link: https://doi.org/10.1177/..
 
?
14

Plateau is a prognostic factor of lenalidomide therapy for ..:

Takakuwa, Teruhito ; Ohta, Kensuke ; Nakatani, Eiji...
Hematological Oncology.  39 (2021)  3 - p. 349-357 , 2021
Link: https://doi.org/10.1002/..
 
?
15

Outcomes of ixazomib/lenalidomide/dexamethasone for multipl..:

Takakuwa, Teruhito ; Yamamura, Ryosuke ; Ohta, Kensuke...
European Journal of Haematology.  106 (2021)  4 - p. 555-562 , 2021
Link: https://doi.org/10.1111/..
 
1-15